Redwire expands space-based pharmaceutical research under new NASA contract
by Clarence Oxford
Los Angeles CA (SPX) Mar 26, 2025

Redwire Corporation (NYSE: RDW), a space infrastructure company serving the growing space economy, has secured a new NASA contract to send four additional pharmaceutical studies to the International Space Station. These investigations will utilize Redwire's proprietary Pharmaceutical In-space Laboratory (PIL-BOX) to support production of high-value seed crystals, laying the groundwork for future drug manufacturing in orbit aboard both government and private space stations.

"NASA has been an instrumental partner and customer as we've scaled our pharmaceutical drug manufacturing program significantly over the last year," said John Vellinger, Redwire's President of In-Space Industries. "Additional PIL-BOX investigations from NASA and commercial partners will enable Redwire to optimize the infrastructure to launch, test, manufacture, and return high-value space enabled pharmaceutical products and establish a new market in LEO"

The PIL-BOX platform, which has already completed 28 missions, offers pharmaceutical developers access to microgravity to cultivate small-batch crystals of protein-based drugs and other biologically relevant compounds. This low Earth orbit environment provides unique conditions for growing more uniform and less defective crystals, a factor that can accelerate drug development and improve formulation quality.

Previous experiments using PIL-BOX have contributed valuable data in the quest to enhance therapies for conditions such as cardiovascular disease, obesity, and diabetes, showcasing the broader potential of space-enabled research.

Related Links
Redwire
Space Technology News - Applications and Research